EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...
Regulatory ApprovalFormycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / 06:30 CET/CESTThe issuer is solely ...
REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea ...
Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...
After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...
Regeneron’s lead drug, Eylea (aflibercept), is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. To counter the ongoing decline in Eylea sales ...
Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to "Neutral" from "Buy" given uncertainty ...
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar ...
Teva Pharmaceutical collaborates with Klinge Biopharma and Formycon AG to commercialize Formycon's biosimilar candidate to ...
If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback